New drug TAK-279 (zasocitinib) shows promise for #PsA Significantly improved symptoms in patients after 12 weeks compared to placebo & well-tolerated. Fewer targeted oral therapies exist, making zasocitinib a potential new option. #EULAR24 #PsA IH https://t.co/RvcONHCLvz